Silence Therapeutics said this week that the opposition division of the European Patent Office has upheld an amended version of its core European patent.
The patent, EP 1527176, entitled "Further Novel Forms of Interfering RNA Molecules," claims a double-stranded, blunt-ended RNA capable of inhibiting a target gene, as well as therapeutic uses thereof. It also claims the use of alternating 2’-O-methyl modifications on the molecules.
According to Silence, the patent's amended claims "no longer cover other chemical modifications and molecular designs not used by Silence and which therefore do not have an impact on Silence’s core business."
The company added that it will "consider whether to appeal this aspect of the EPO’s decision, which followed two days of oral hearings."